What was the total amount repurchased by InfuSystem in the first half of 2026?

InfuSystem repurchased $4.4 million in common stock during the six-month period ended June 30, 2026, including $3.5 million in the second quarter alone. This was executed under the company's ongoing share repurchase program.

Is this a new buyback authorization or an existing program?

This is execution under an existing, ongoing share repurchase program. The filing does not announce a new authorization, amendment, or termination. The original authorization amount and remaining authorization capacity are not disclosed in this earnings report.

What is InfuSystem's financial position to support the buyback?

As of June 30, 2026, InfuSystem had $55.2 million in total available liquidity, consisting of $54.2 million in available revolving credit and $1.0 million in cash. The company's net debt was $19.5 million, with an Adjusted EBITDA-to-net-debt ratio of 0.61x.

How many shares were repurchased and at what price?

The filing does not disclose the number of shares repurchased, the average price paid per share, or the execution mechanism (e.g., Rule 10b-18, ASR, or 10b5-1 plan). Only the dollar amounts ($4.4 million for H1 and $3.5 million for Q2) are provided.

What is InfuSystem's business and why might it conduct buybacks?

InfuSystem is a healthcare service provider facilitating outpatient care for durable medical equipment manufacturers and healthcare providers. The company operates two platforms: Patient Services (Oncology, Pain Management, Wound Therapy) and Device Solutions (rentals, biomedical services). Buybacks are typically used to return capital to shareholders and manage share count.

Is the buyback program likely to continue?

The filing describes the repurchases as part of an 'ongoing share repurchase program,' suggesting the company intends to continue, but no specific authorization details or future guidance on repurchase volume is provided. Future activity depends on capital allocation priorities and available liquidity.

INFU 8-K Filed 2026-08-04 Execution disclosure

InfuSystem repurchased $4.4M in stock in H1 2026

Healthcare provider executes ongoing buyback program; $3.5M repurchased in Q2 alone

MechanismNot specified

What the filing says

InfuSystem Holdings, Inc. (NYSE American: INFU) repurchased $4.4 million in common stock during the first half of 2026 under its ongoing share repurchase program, with $3.5 million of that total executed in the second quarter ended June 30, 2026. The cash-flow statement shows total repurchase activity of $4.358 million for the six-month period.

The company reported liquidity of $55.2 million as of June 30, 2026, consisting of $54.2 million in available borrowing capacity and $1.0 million in cash and equivalents. Net debt stood at $19.5 million (total debt of $20.4 million less cash of $1.0 million), representing a $3.0 million increase from year-end 2025. The company's ratio of Adjusted EBITDA to net debt was 0.61 to 1.00.

The filing does not disclose the specific authorization amount, authorization date, remaining authorization, average share price paid, or execution mechanism (Rule 10b-18, ASR, 10b5-1 plan, or other). The repurchase is characterized as an "ongoing share repurchase program," indicating it operates under a previously established authorization, but no new authorization or amendment is announced in this filing.

Stock Repurchases totaled $3.5 million for the quarter. Also, during 2026 the Company used cash to repurchase $4.4 million in common stock under the Company's ongoing share repurchase program. — InfuSystem Holdings, Inc 8-K filing · View on SEC EDGAR →

What this means

InfuSystem's execution of $4.4 million in share repurchases during the first half of 2026 represents a return of capital to shareholders while the company maintains operational liquidity. With $55.2 million in total available liquidity and a net-debt-to-Adjusted-EBITDA ratio of 0.61x, the company appears to have sufficient financial flexibility to continue repurchases. The repurchase activity is modest relative to the company's market position, and no new authorization or expansion of the program is disclosed in this earnings report. The company reaffirmed full-year 2026 guidance for 6–8% pro forma revenue growth and mid-to-low 20% Adjusted EBITDA margins.

Frequently asked questions

What was the total amount repurchased by InfuSystem in the first half of 2026?: InfuSystem repurchased $4.4 million in common stock during the six-month period ended June 30, 2026, including $3.5 million in the second quarter alone. This was executed under the company's ongoing share repurchase program.
Is this a new buyback authorization or an existing program?: This is execution under an existing, ongoing share repurchase program. The filing does not announce a new authorization, amendment, or termination. The original authorization amount and remaining authorization capacity are not disclosed in this earnings report.
What is InfuSystem's financial position to support the buyback?: As of June 30, 2026, InfuSystem had $55.2 million in total available liquidity, consisting of $54.2 million in available revolving credit and $1.0 million in cash. The company's net debt was $19.5 million, with an Adjusted EBITDA-to-net-debt ratio of 0.61x.
How many shares were repurchased and at what price?: The filing does not disclose the number of shares repurchased, the average price paid per share, or the execution mechanism (e.g., Rule 10b-18, ASR, or 10b5-1 plan). Only the dollar amounts ($4.4 million for H1 and $3.5 million for Q2) are provided.
What is InfuSystem's business and why might it conduct buybacks?: InfuSystem is a healthcare service provider facilitating outpatient care for durable medical equipment manufacturers and healthcare providers. The company operates two platforms: Patient Services (Oncology, Pain Management, Wound Therapy) and Device Solutions (rentals, biomedical services). Buybacks are typically used to return capital to shareholders and manage share count.
Is the buyback program likely to continue?: The filing describes the repurchases as part of an 'ongoing share repurchase program,' suggesting the company intends to continue, but no specific authorization details or future guidance on repurchase volume is provided. Future activity depends on capital allocation priorities and available liquidity.

execution healthcare-services ongoing-program mid-cap share-repurchase

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.